Periodontal diseases are among the most common microbial infections in adults and the prime treatment option for periodontal diseases involves mechanical debridment – scaling and root planing (SRP). Research in recent years in periodontology has seen a shift from surgery towards medicine. Scaling and root planing is sometimes followed by adjunctive therapy such as local delivery antimicrobials, systemic antibiotics, and host modulation, as needed on a case-by-case basis. Dentists and microbiologists across the globe have embraced the usage of antibiotics as an adjunctive therapy for management of periodontal diseases. The antimicrobials have included metronidazole in an ointment form (Elyzol), chlorhexidine (Periochip) as well as doxycycline either in a fiber form (Actisite), or also in a polymeric delivery system (Atridox). World Health Organization (WHO) estimates about 60% to 90% of the school-age children and vast majority of adults with dental caries as a major public health problem in the highest income countries.
The global periodontal disease therapeutics market report provides market size (Revenue US$ Million 2014 to 2021), market share, market trends and forecasts growth trends (CAGR%, 2017 to 2021).
The global periodontal disease therapeutics market segmentation is based on drug types (Arestin, Atridox, Doxycycline, Metronidazole, Minocycline, PerioChip).
The global periodontal disease therapeutics market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global periodontal disease therapeutics market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.
Major players operating in the global periodontal disease therapeutics market and included in this report are 3M, DenMat Holdings LLC, Dexcel Pharma, Galderma SA, Kaken Pharmaceuticals, and Valeant Pharmaceutical.